跳转至内容
Merck
CN

M-123

Supelco

酒石酸美托洛尔标准液 酒石酸酯 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C15H25NO3 · 0.5 C4H6O6
化学文摘社编号:
56392-17-7
分子量:
342.41
EC 号:
200-659-6
MDL编号:
MFCD23141017
UNSPSC代码:
41116107
PubChem化学物质编号:
329817863
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

certified reference material

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

2-8°C

SMILES字符串

CC(C)NCC(COC1=CC=C(CCOC)C=C1)O.CC(C)NCC(COC2=CC=C(CCOC)C=C2)O.OC(C(O)=O)C(C(O)=O)O

InChI

1S/2C15H25NO3.C4H6O6/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-1(3(7)8)2(6)4(9)10/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)

InChI key

YGULWPYYGQCFMP-UHFFFAOYSA-N

基因信息

human ... ADRB1(153)

相关类别

一般描述

经认证的溶液标准品，适用于通过LC-MS/MS或GC/MS进行临床毒理学或法医分析。美托洛尔用于多种心脏病的治疗，包括高血压，心绞痛和心动过速。这种β受体阻滞剂以Lepressor和Toprol XL®的商品名出售。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Toprol XL is a registered trademark of Astrazeneca AB

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Thomas Kahan et al.
European journal of clinical investigation, 43(2), 141-151 (2013-01-03)
Although stable angina pectoris often carries a favourable prognosis, it remains important to identify patients with an increased risk of cardiovascular (CV) complications. Many new markers of disease activity and prognosis have been described. We evaluated whether common and easily
Iu M Alekseeva et al.
Kardiologiia, 52(11), 86-91 (2012-12-15)
We present analysis of a case history of a patient with rare congenital heart disorder - Bland-White-Garland syndrome. The 25 years old women was first diagnosed with this disorder during an examination in the cardiological department of the Moscow clinical
A L Vertkin et al.
Klinicheskaia meditsina, 91(3), 31-35 (2013-06-26)
Patients with acute coronary syndrome and elevated ST segment in the pre-hospital phase were treated with metoprolol succinate (MS) and thrombolytic therapy. Severe and moderate pain decreased by 54.1 and 16.1% respectively within 60 min after MS intake. Systolic (SAP)
V A Iakushev et al.
Sudebno-meditsinskaia ekspertiza, 55(5), 46-48 (2013-01-01)
This paper reports the results of analysis of the metoprolol succinate tablets fabricated by two different manufacturers, Akrikhin (Russia) and AstraZeneka (Sweden) by near-IR spectroscopy in the combination with the chemometric processing of the data obtained (discriminative analysis). It is
Michel De Pauw et al.
Acta cardiologica, 68(2), 205-207 (2013-05-28)
The concept of chronotropic incompetence may have to be fine-tuned in an era of proven benefit of heart rate reducing therapy. It is illustrated in three patients with heart failure referred for heart transplantation evaluation. In patients one and two
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持